FUJI PHARMA CO., LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,474 JPY | -1.73% |
|
-2.90% | -15.24% |
| 2023 | Mithra Pharmaceuticals' License Partner Files for Estelle's Marketing Approval in Japan; Shares Jump | MT |
| 2023 | Alvotech Partner Secures Marketing Approval for Stelara Biosimilar AVT04 in Japan | MT |
Evolution of the average Target Price on Fuji Pharma Co., Ltd.
Price target over the last 5 years
History of analyst recommendation changes
2d2f499aa8ce1ae34a8355a4e26.GgkYE2bFN2xLcUrJ3XHzqQif4U5SsOKzaCc_Vk5gZA8.YzhwegS9UCIUOXq4k1y_mEnb2AoKnYP1Bl1NYygWHl1tYnAlJZJVJB46eg~47c908c972928f38613e3c2bb67f3b6b
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1,500
JPY
Average target price
2,057
JPY
Spread / Average Target
+37.11%
High Price Target
2,170
JPY
Spread / Highest target
+44.67%
Low Price Target
2,000
JPY
Spread / Lowest Target
+33.33%
Consensus detail
Consensus revision (last 18 months)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
- Stock Market
- Equities
- 4554 Stock
- Consensus Fuji Pharma Co., Ltd.
